Oncology

Validation of KQ-791 in combination immunotherapies cancer models

Challenge: The knowledge gained in cancer immunology has increased the list of new therapeutic applications. Yet, these approaches (CAR-T, check-point inhibitors and others) are still suffering from several drawbacks, among them: very high cost, more complex biological or/and cellular-based technologies, lack of efficiency against solid tumours, difficulties in validating multiple combination therapies, increased difficulty in selection […]

Validation of KQ-791 in combination immunotherapies cancer models Read More »

Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia

Challenge: Acute leukemia is the most common blood cancer in children. Aggressive chemotherapy and radiation treatments cure about 80% of affected children. However, they are not perfect cures since a part of children is incurable and dies of leukemia and these treatments kill not only the cancer cells, but also the healthy ones. As a result,

Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia Read More »

Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma

Challenge: The Chimeric Antibody Receptor (CAR) presents a promising avenue in cancer immunotherapy by engineering patients’ T cells to express CAR molecules, enabling targeted recognition and elimination of tumor cells. While CAR-T therapy has demonstrated notable success in inducing remission for B cell leukemia, lymphoma, and multiple myeloma, it has failed in non-hematologic solid tumors, with

Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma Read More »

Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias

Challenge: Despite improvements in the treatment of many pediatric cancers, high-risk subtypes such as acute myeloid leukemia (AML) and acute megakrayoblastic leukemia (AMKL) still have amongst the worst prognosis, with only ~40-60% survival at 5-years. There is therefore a critical unmet medical need for novel targeted treatments but to completely eradicate the tumor cells these treatments

Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias Read More »

Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers

Challenge: Cancers with metastases are responsible for 90% of cancer deaths. Unfortunately, metastases often become refractory to treatment and although certain molecules are theoretically able to act on these tumors, their non-targeted administration greatly limits their effectiveness. Solution: This project aims to validate the efficacy of the peptide-drug (TH1902) on secondary tumors by characterizing its mechanisms of

Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers Read More »

Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer

Challenge: Because of their immunosuppressive properties, galectins play a critical role in many diseases, most notably in cancer. Some galectins can suppress the immune response by inducing the death of cells that are protecting against cancer cells development. Galectins can also promote tumor cell growth by preventing tumor infiltration by immune cells. For these reasons,

Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer Read More »

Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment

Challenge: Cancer therapy has been transformed in recent years by the impressive success of immunotherapy using immune checkpoint inhibitors. However, the success of immunotherapy in some types of cancers, including prostate cancer (PCa), has been rather limited. A major challenge facing the development of PCa immunotherapy is the identification of tumors that would best respond

Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment Read More »

Development of immunotherapy for bladder cancer using IMV’s drug delivery platform

Challenge: Bladder cancer is 5 th in frequency in Canada. Each year, approximately 80,000 people will be diagnosed with bladder cancer and more than 20 % of them will die from the disease. The treatment of advanced bladder cancer has been revolutionized in the recent years by the impressive clinical success of immune checkpoint (IC)-based immunotherapy. Advanced bladder

Development of immunotherapy for bladder cancer using IMV’s drug delivery platform Read More »

A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers

Challenge: Extensive characterization of tumors is central to the development of personalized therapies such as immunotherapy, now considered one of the most promising approaches to cancer treatment. The capability to detect a multitude of biomarkers simultaneously on the same tissue section would provide unprecedented headways in the field of cancer research and particularly on tumor

A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers Read More »

Macrocyclic peptides as the next-generation immuno-oncology therapeutics

Challenge: When considering drug discovery, the pharmaceutical industry faces many challenges. Indeed, each drug class, namely small molecules, antibodies or peptides-based therapeutics, possesses its own characteristics and comes with its own challenges. While presenting similar features than peptides in terms of activity, selectivity and potency, macrocycle peptides also present enhanced permeability and stability towards proteases.

Macrocyclic peptides as the next-generation immuno-oncology therapeutics Read More »

Scroll to Top